Terms: = Germ cell tumor AND H3F3A, P84243, H3_3B, MGC87783, MGC87782, H3F3, H3_3A, ENSG00000163041, 3020
223 results:
1. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
[TBL] [Abstract] [Full Text] [Related]
2. Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics.
Haggenmüller S; Schmitt M; Krieghoff-Henning E; Hekler A; Maron RC; Wies C; Utikal JS; Meier F; Hobelsberger S; Gellrich FF; Sergon M; Hauschild A; French LE; Heinzerling L; Schlager JG; Ghoreschi K; Schlaak M; Hilke FJ; Poch G; Korsing S; Berking C; Heppt MV; Erdmann M; Haferkamp S; Drexler K; Schadendorf D; Sondermann W; Goebeler M; Schilling B; Kather JN; Fröhling S; Brinker TJ
JAMA Dermatol; 2024 Mar; 160(3):303-311. PubMed ID: 38324293
[TBL] [Abstract] [Full Text] [Related]
3. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
[TBL] [Abstract] [Full Text] [Related]
4. Intraoperative Integrated Diagnostic System for Malignant Central Nervous System tumors.
Hayashi T; Tateishi K; Matsuyama S; Iwashita H; Miyake Y; Oshima A; Honma H; Sasame J; Takabayashi K; Sugino K; Hirata E; Udaka N; Matsushita Y; Kato I; Hayashi H; Nakamura T; Ikegaya N; Takayama Y; Sonoda M; Oka C; Sato M; Isoda M; Kato M; Uchiyama K; Tanaka T; Muramatsu T; Miyake S; Suzuki R; Takadera M; Tatezuki J; Ayabe J; Suenaga J; Matsunaga S; Miyahara K; Manaka H; Murata H; Yokoyama T; Tanaka Y; Shuto T; Ichimura K; Kato S; Yamanaka S; Cahill DP; Fujii S; Shankar GM; Yamamoto T
Clin Cancer Res; 2024 Jan; 30(1):116-126. PubMed ID: 37851071
[TBL] [Abstract] [Full Text] [Related]
5. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
[TBL] [Abstract] [Full Text] [Related]
6. A comprehensive genomic study of 390 h3f3a-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract] [Full Text] [Related]
7. Correlation between Multiparametric MR Imaging and Molecular Genetics in Pontine Pediatric High-Grade Glioma.
Rameh V; Vajapeyam S; Ziaei A; Kao P; London WB; Baker SJ; Chiang J; Lucas J; Tinkle CL; Wright KD; Poussaint TY
AJNR Am J Neuroradiol; 2023 Jul; 44(7):833-840. PubMed ID: 37321859
[TBL] [Abstract] [Full Text] [Related]
8. Mutational landscape of primary spinal cord astrocytoma.
Cheng L; Zhang F; Zhao X; Wang L; Duan W; Guan J; Wang K; Liu Z; Wang X; Wang Z; Wu H; Chen Z; Teng L; Li Y; Xiao F; Fan T; Jian F
J Pathol; 2023 Jul; 260(3):317-328. PubMed ID: 37114614
[TBL] [Abstract] [Full Text] [Related]
9. Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma.
Zhang Q; Yang L; Liu YH; Wilkinson JE; Krainer AR
Sci Transl Med; 2023 Apr; 15(691):eadd8280. PubMed ID: 37043556
[TBL] [Abstract] [Full Text] [Related]
10. Update on quality assurance in neuropathology: Summary of the round robin trials on
Pohl S; Dimitrova L; Grassow-Narlik M; Jöhrens K; Acker T; Dohmen H; Herms J; Dorostkar M; Hartmann C; Hasselblatt M; Neumann M; Reifenberger G; Felsberg J; Schüller U; Zoubaa S; Lorenz J; Rothhammer-Hampl T; Mauch-Mücke K; Riemenschneider MJ
Clin Neuropathol; 2023; 42(3):112-121. PubMed ID: 36999511
[TBL] [Abstract] [Full Text] [Related]
11. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
[No Abstract] [Full Text] [Related]
12. Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence.
Tamura R; Iwanami A; Ohara K; Nishimoto M; Pareira ES; Miwa T; Tsuzaki N; Kuranari Y; Morimoto Y; Toda M; Okano H; Nakamura M; Yoshida K; Sasaki H
Brain Tumor Pathol; 2023 Apr; 40(2):109-123. PubMed ID: 36892668
[TBL] [Abstract] [Full Text] [Related]
13. Co-occurrence of mutations in
Mellid S; Gil E; Letón R; Caleiras E; Honrado E; Richter S; Palacios N; Lahera M; Galofré JC; López-Fernández A; Calatayud M; Herrera-Martínez AD; Galvez MA; Matias-Guiu X; Balbín M; Korpershoek E; Lim ES; Maletta F; Lider S; Fliedner SMJ; Bechmann N; Eisenhofer G; Canu L; Rapizzi E; Bancos I; Robledo M; Cascón A
Front Endocrinol (Lausanne); 2022; 13():1070074. PubMed ID: 36760809
[TBL] [Abstract] [Full Text] [Related]
14. Impact of epigenetic reprogramming on antitumor immune responses in glioma.
McClellan BL; Haase S; Nunez FJ; Alghamri MS; Dabaja AA; Lowenstein PR; Castro MG
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647827
[TBL] [Abstract] [Full Text] [Related]
15. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
Kibe Y; Motomura K; Ohka F; Aoki K; Shimizu H; Yamaguchi J; Nishikawa T; Saito R
Sci Rep; 2023 Jan; 13(1):23. PubMed ID: 36646712
[TBL] [Abstract] [Full Text] [Related]
16. The clinicopathological features and prognosis of multifocal high-grade gliomas in adults with
Zhao Y; Chen Y; Wang L; Gao Y; Xu J
Neurosciences (Riyadh); 2023 Jan; 28(1):42-47. PubMed ID: 36617452
[TBL] [Abstract] [Full Text] [Related]
17. Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients.
Parisi R; Patel RR; Rood G; Bowden A; Turco G; Korones DN; Andolina JR; Comito M; Barth M; Weintraub L
Pediatr Blood Cancer; 2023 Mar; 70(3):e30139. PubMed ID: 36573296
[TBL] [Abstract] [Full Text] [Related]
18. IDH-mutant brainstem glioma.
Ryzhova MV; Galstyan SA; Telysheva EN; Pitskhelauri DI; Kosyrkova AV; Latyshev YA
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(6):52-57. PubMed ID: 36534624
[TBL] [Abstract] [Full Text] [Related]
19. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract] [Full Text] [Related]
20. Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort study.
Kapteijn MY; Kaptein FHJ; Stals MAM; Klaase EE; García-Ortiz I; van Eijk R; Ruano D; van Duinen SG; Cannegieter SC; Taphoorn MJB; Dirven L; Koekkoek JAF; Klok FA; Versteeg HH; Buijs JT
Thromb Res; 2023 Jan; 221():10-18. PubMed ID: 36435047
[TBL] [Abstract] [Full Text] [Related]
[Next]
